PYC Shares PYC Therapeutics Limited

ASX · ASX

$1.78 +1.14% Prices as of close 2026-10-26

Last in our picks 2026-10-26 — not in the current list; analysis below is from that screen

Positive broker target increase, strong cash balance, and near-term efficacy data support substantial rerating potential.

Future value: $4.07 (+131.91%) · 6-12 months · analyst consensus

Signal breakdown

▸Bell Potter raised target to $3.00; efficacy data expected within months.
▾Below 50-day MA (-24.66%)
▸Above 200-day MA — long-term uptrend
▸~132% upside to price target

Is PYC a buy right now?

Trend: PYC is trading below the 50-day average (-23.49%), RSI 41 — neutral momentum, with a 3-month return of +5.97%.

Valuation & quality: PYC Therapeutics Limited trades on forward P/E -21.2, price-to-book 2.52; fundamentals show net margin -166.7%, return on equity -10.1%, revenue growth 46.6% year on year.

Analyst consensus: 5 analysts have a mean 12-month price target of A$4.07 (+129.3% vs the last close; range A$3.20 – A$5.00), consensus rating “strong buy”.

Our screen: STRONG BUY (score 4) — Positive broker target increase, strong cash balance, and near-term efficacy data support substantial rerating potential.

Computed from end-of-day data; not personal advice.

Our track record with PYC

Our simulated $10,000 funds have traded PYC 2 times — 2 of 2 closed trades profitable.

Fund	Bought	Sold	Return
ASX High-risk	2026-10-01 @ $2.51	2026-10-08 @ $2.53 · Defensive switch	+0.80%
ASX High-risk	2026-08-22 @ $2.10	2026-09-01 @ $2.32 · Monthly rebalance	+10.48%

Paper trades from our simulated funds at real end-of-day prices; past results don't predict future returns.

12-month price chart

Daily close, 2026-02-08 → 2026-10-26 (AUD). Range 1.07 – 2.91.

Monthly returns

Mar 26	Apr 26	May 26	Jun 26	Jul 26	Aug 26	Sep 26	Oct 26
-22.70%	+8.60%	+7.10%	+24.40%	+1.20%	+36.50%	+15.50%	-34.00%

Fundamentals

Market cap

$1.75B

P/E (ttm)

-21.0

Forward P/E

-21.2

EPS (ttm)

$-0.06

Price / book

2.52

Beta

1.01

Net margin

-166.7%

ROE

-10.1%

Revenue growth

46.6%

Revenue (ttm)

$26.0M

Free cash flow

$-40,093,944

Debt / equity

52-wk range

$1.05 – $2.93

Volume

5,321

Avg volume (3m)

3,739,603

Analyst price target

Mean target

$4.07

Low

$3.20

High

$5.00

Analysts

Consensus

STRONG BUY

Technical signals

RSI (14)

41.4

vs 50-day MA

-23.49%

1-mo return

-35.45%

3-mo return

+5.97%

Volume z-score

-0.43

About PYC Therapeutics Limited

PYC Therapeutics Limited, a clinical stage drug-development company, engages in the discovery and development of novel RNA therapeutics for the treatment of genetic diseases in Australia.

Sector: Healthcare · Industry: Biotechnology · Australia · Website

Related Biotech picks

CSL.AXCSL Limited MSB.AXMesoblast Limited IMR.AXImricor Medical System SLD.AXSaluda Medical, Inc.NUZ.AXNeurizon Therapeutics NEU.AXNeuren Pharmaceuticals DXB.AXDimerix Limited NYR.AXNyrada Inc.

Browse: all ASX stocks · Biotech picks · today's movers

General information only (Australia). This is general information, not financial product advice. It doesn't consider your objectives, financial situation or needs — consider its appropriateness and seek licensed advice before acting. Not a recommendation to buy or sell any financial product.

Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.